ライフサイエンスコーパス: type 4

1 nd death from toxicity or unknown recurrence type, 4%.

2 ly susceptible to infection by dengue virus (type 4).

3 or Pendulous (Type 3) and Creased or Ridged (Type 4).

4 RPV4 (transient receptor potential vanilloid type 4).

5 ression ratio for HDAC4 (histone deacetylase type-4).

6 idemiology and clinical presentation of HPIV type 4.

7 tes and maturity-onset diabetes of the young type 4.

8 in, alpha(X)beta(2), the complement receptor type 4.

9 3 than after dose 2 for all serotypes except type 4.

10 ly identified B. anthracis pagA types except type 4.

11 ies, 17 (20%) with type 3, and 12 (16%) with type 4.

12 ions in SOX10 result in Waardenburg syndrome type 4.

13 her known adenoviruses, including adenovirus type 4.

14 ting factor and the C-X-C chemokine receptor type 4.

15 d death (three of 13 [23%]) occurred only in type 4.

16 ferroptotic mediator, glutathione peroxidase type 4.

17 in is greatly reduced compared with the wild type; 4.

18 up to six distinct, narrowly tuned spectral types [4].

19 -13 only in T cells (4-13Tko) or in all cell types (4-13ko).

20 tide precursor and may involve a Diels-Alder-type [4 + 2] cycloaddition reaction.

21 978 DeltapstS was lower compared to the wild type (4.3 vs 3.2 log colony forming units/mL, respective

22 t (scFv) contains 14 mutations from the wild-type 4-4-20 scFv and has a 1800-fold increase in fluores

23 Seroprevalence was highest for HPV types 4 (46%), 1 (37%), and 8 (31%) in men and for types

24 4 (46%), 1 (37%), and 8 (31%) in men and for types 4 (47%), 63 (34%), and 1 (33%) in women.

25 sulin-stimulated NO release (mean [SEM] wild type 4,500 AU [1,000], hIGFREO 1,500 AU [700]; P < 0.05)

26 n those observed in the wild-type mice (wild-type, 4.58 +/- 0.25 mm; transgenic, 9.83 +/- 1.05 mm).

27 .008 for skin type 2, and P < .001 for skin types 4-6).

28 gether with the variability observed in wild-type [4] [6] and genetically manipulated mice ([6] and o

29 In a staged approach, we first typed 4,608 SNPs in case-control populations from four U

30 yos from matings of Hdh (+/-) mice with wild-type 4-8 cell embryos.

31 2.41 [95% CI, 1.24-4.70]); maternal AB blood type (4.9% stillbirths, 3.0% live births) (vs type O; AO

32 s significantly reduced compared to the wild type, 4.9 +/- 0.5 micromol/min/mg of protein (n = 7) and

33 dy, we tested whether adeno-associated virus type 4 (AAV4) vectors could mediate global functional an

34 The structure of AAV type 4 (AAV4), one of the most antigenically distinct se

35 We found that the CXC chemokine receptor type 4 accommodated the results better than the other te

36 Infections of adenovirus type 4 (Ad4) and Ad7 were discovered among previously va

37 report the x-ray crystal structure of the Ad type 4 (Ad4) E3-19K of species E bound to HLA-A2 at 2.64

38 e using a low-seroprevalent human Adenovirus type 4 (Ad4-prM-E) and compared it to an Ad5 vector (Ad5

39 ear hiatus, oral vaccines against adenovirus types 4 (Ad4) and 7 (Ad7) were again produced and admini

40 agonist (Lotronex, GlaxoSmithKline) and 5-HT type 4 agonist (Zelnorm, Novartis, AB) drugs on the dyna

41 asymmetric reduction of prochiral ketones of type 4-alkylidene cyclohexanone with formation of the co

42 (transforming growth factor beta1, collagen type 4 alpha 1, matrix metalloproteinase 2, and alpha-sm

43 We report that collagen type 4 alpha3-deficient mice with Alport syndrome-relate

44 e 2 (AOA2) and amyotrophic lateral sclerosis type 4 (ALS4).

45 (Fpn)], are responsible for hemochromatosis type 4, also known as ferroportin disease.

46 a strong influence of the stereochemistry of type 4 aminotetraline-derived agonists on functional sel

47 ease of antiangiogenic fragments of collagen type 4 and 18.

48 Although the HAdV type 4 and 7 vaccine is currently given to US military e

49 Administration of the HAdV type 4 and 7 vaccine may benefit this cohort.

50 and compare the spectroscopic properties of type 4 and type 1 CRYs.

51 uppressed EGFR, whereas E1A12S of adenovirus types 4 and 40 had no effect on EGFR expression.

52 of electrophysiological cell phenotypes from types 4 and 5 cells (astrocytes) to type 1 cells (neuron

53 Type 2 and 3 cells expressed DCX, types 4 and 5 cells expressed GFAP, and type 1 cells exp

54 th (types 1, 2, and 3) or procedure related (Types 4 and 5) and examined events occurring early and a

55 emi-formed stools (Bristol Stool Form Scale, Types 4 and 5) per day with no nocturnal diarrhea, urgen

56 the attachment receptors for AAV type 2 and types 4 and 5, respectively.

57 ites (types 1, 4, and 6), Solanum pennellii (types 4 and 6), Solanum arcanum (type 6), and Solanum pi

58 tagonized by CXCR4 (C-X-C chemokine receptor type 4) and regulated the outer topology of neutrophils

59 l cell-derived factor-1+, chemokine receptor type 4+, and von Willebrand factor+ cells, and vessels i

60 After 46.6+/-4.3 days, CLG type 2, type 4, and purified CLG were applied in vitro (n=1) to

61 to the G protein coupled chemokine receptor type 4, and the identification of permeation pathways th

62 on one type 1, six type 2, two type 3, eight type 4, and two type 5 lesions were identified on T2-wei

63 2B; Marfan syndrome; Ehlers-Danlos syndrome type 4; and juvenile glaucoma.

64 he basal ganglia and cerebellum and dystonia type 4 are the extremes.

65 s with dengue virus type 2 (and dengue virus type 4) are largely subclinical.

66 entiation 36) and GLUT4 (glucose transporter type 4), are also unchanged.

67 in the mouse retina, the cone photoreceptor type 4 bipolar cell (BC4) synapse, and show that its dev

68 Some types of OFF bipolar cells, type 3b and type 4 bipolar cells, had defects in dendrite arborizati

69 ypes of bipolar cells, including type 3b and type 4 bipolar cells.

70 As bone morphogenetic protein type 4 (BMP4) regulates Msx2 expression in embryonic tis

71 Male smokers, maxillary first molars, and type 4 bone had increased failure rates.

72 V-11, -16, and -18 and bovine papillomavirus type 4 (BPV-4) E2 and is also required for the respectiv

73 The expression of bovine papillomavirus type 4 (BPV-4) E7 overcame this arrest and lead to the d

74 Using type-4 BRET assays, we investigate heterodimerization am

75 sonance energy transfer (BRET) assay, called type-4 BRET, which detects both homo- and heteromeric in

76 wo-dimensional (2D) elastic crystals, of the type 4-bromophenyl 4'-nitrobenzoate where the halogen bo

77 ntification of the gene (NPHP4) causing NPHP type 4, by use of high-resolution haplotype analysis and

78 By blocking cAMP degradation, type 4 cAMP phosphodiesterase (PDE4) inhibitors activate

79 P signaling pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801

80 ted LPS responses in mice deficient in PDE4 (type 4 cAMP-specific PDE)-B and PDE4D.

81 nd the combination of C-C chemokine receptor type 4 (CCR4) chemokine receptors and beta1 and beta3 in

82 T cells and Th2 cells via their receptor CCR type 4 (CCR4).

83 ceptor type 5 and chemokine-related receptor type 4 (CCR5 and CXCR4) on peripheral blood mononuclear

84 s strongly expressed by diffuse cone bipolar type 4 cells (DB4; marked with anti-PKCalpha) and weakly

85 -insensitive K(+) and small Na(+) currents; type 4 cells, with slowly activating, large linear outwa

86 e-2 vasopressin, type-1 angiotensin, and CXC type-4 chemokine receptors, but not for the prostaglandi

87 tion into 5 pulsed-field gel electrophoresis types, 4 coagulase types, and 2 ribotypes.

88 stains, and labels immunohistochemically for type 4 collagen.

89 amide, i.e. a blood group O determinant on a type 4 core chain, the generalist strain bound to the Gl

90 1Cer), i.e. a blood group A determinant on a type 4 core chain.

91 d Arabidopsis CRY1 neither insect type 1 nor type 4 CRYs have autokinase activities.

92 Here we describe the purification of type 4 CRYs of zebrafish and chicken as recombinant prot

93 d receptors (GPCRs) C-X-C chemokine receptor type 4 (CXCR4) and atypical chemokine receptor 3 (ACKR3)

94 y the inhibitors of C-X-C chemokine receptor type 4 (CXCR4) and C-C chemokine receptor type 1 (CCR1),

95 The C-X-C motif chemokine receptor type 4 (CXCR4) and the atypical chemokine receptor 3 (AC

96 g overexpression of C-X-C chemokine receptor type 4 (CXCR4) and upregulation of plasminogen activator

97 r mechanism for the C-X-C chemokine receptor type 4 (CXCR4) antagonist 1 (AMD3100), a template with t

98 that antagonism of C-X-C chemokine receptor type 4 (CXCR4) by plerixafor (AMD3100) can decrease regu

99 over, Plg regulated C-X-C chemokine receptor type 4 (CXCR4) expression in stem cells in vivo and in v

100 high expression of C-X-C chemokine receptor type 4 (CXCR4) mutation in Waldenstrom macroglobulinemia

101 The SDF-1alpha/C-X-C receptor type 4 (CXCR4) pathway directly promotes hepatic stellat

102 The C-X-C chemokine receptor type 4 (CXCR4) plays a crucial role in modulating cell t

103 very high levels of C-X-C chemokine receptor type 4 (CXCR4) production.

104 ively targeting the C-X-C chemokine receptor type 4 (CXCR4) was found to be an allosteric agonist, ac

105 ion of the cytokine C-X-C chemokine receptor type 4 (Cxcr4), an established regulator of this process

106 itory activity on the CXC chemokine receptor type 4 (CXCR4), toxicity properties, and assessment of t

107 The C-X-C chemokine receptor type 4 (CXCR4)/stromal cell derived factor-1 (SDF-1 or C

108 Type 4 cyclic adenosine monophosphate (cAMP) phosphodies

109 tosis following treatment with inhibitors of type 4 cyclic nucleotide phosphodiesterase (PDE4), a pro

110 Here, we provide evidence that type 4 cyclic nucleotide phosphodiesterases (PDE4s) are

111 The live attenuated dengue virus type 4 (DEN-4) vaccine candidate virus rDEN4 Delta 30 wa

112 which was originally created in dengue virus type 4 (DEN4) by the removal of nucleotides 172 to 143 f

113 harge-to-alanine mutagenesis of dengue virus type 4 (DEN4) NS5 gene generated a collection of attenua

114 A recombinant live attenuated dengue virus type 4 (DEN4) vaccine candidate, 2ADelta30, was found pr

115 achieved by chimerization with dengue virus type 4 (DEN4).

116 ibody (MAb) 5H2 is specific for dengue virus type 4 (DENV-4) and neutralizes the virus at a high tite

117 Three dengue virus type 4 (DENV-4) vaccine candidates containing deletions

118 rders, type 3 (e.g., hepatitis C virus), and type 4 (dicistroviruses).

119 wed type 3 disease (n = 35), and 9.5% showed type 4 disease (n = 5).

120 Dystonia type 4 (DYT4) was first described in a large family from

121 is mutated in the movement disorder dystonia type 4 (DYT4).

122 (HSV-1) VP22 (HVP22) and equine herpesvirus type 4 (EHV-4) tk (Etk) were constructed in order to eva

123 an early infantile epileptic encephalopathy type 4 (EIEE4) patient carrying a de novo mutation in ST

124 lated to its inhibition of phosphodiesterase type 4 enzymatic activity.

125 cule full agonists of the prostaglandin E(2) type 4 (EP(4)) receptor have been generated and evaluate

126 or macrophage-specific deletion of the PGE2 type 4 (EP4) receptor induced salt-sensitive hypertensio

127 We also identified coherent type 4 feed-forward loops within this ML-hGRN; PuHox52 r

128 Familial Hemophagocytic Lymphohistiocytosis type 4 (FHL4) patient.

129 familial hemophagocytic lymphohistiocytosis type 4 (FHL4), a life-threatening disease of severe hype

130 esponse modelling with a variety of particle types (>4), for the first-time a particle track structur

131 it, IL-3Ralpha, and C-X-C chemokine receptor type 4 from either human ECs or embryonic quail vessel e

132 Genogroup 2 type 4 (GII.4) has been the dominant norovirus genotype

133 and objective response, glucose transporter type 4 (GLUT4) expression, and KIT/PDGFRA mutation statu

134 persistent cell surface glucose transporter type 4 (GLUT4) in adipocytes resulting from impaired fun

135 The glucose transporter type 4 (glut4) is critical for metabolic homeostasis.

136 f the insulin-responsive glucose transporter type 4 (GLUT4) protein in 1988 inspired its molecular cl

137 cyclohydrolase-mediated glucose transporter type 4 (GLUT4) translocation.

138 ately 31%) the levels of glucose transporter type 4 (GLUT4) without affecting the Akt pathway.

139 eased mRNA expression of glucose transporter type 4 (GLUT4), lipoprotein lipase (LpL), peroxisome pro

140 -stimulated recycling of glucose transporter type 4 (Glut4), which is required for glucose homeostasi

141 function in delivery of glucose transporter type 4 (GLUT4)-containing vesicles to the plasma membran

142 pproximately 2-fold) and glucose transporter type 4 (GLUT4; approximately 1.3-fold) levels in WAT in

143 The glucose transporter type-4 (GLUT4) is primarily responsible for the insulin-

144 served residues and motifs characteristic of type 4 group A pilins.

145 3)-D-Asn-L-Lys(3) bridges replacing the wild-type 4-->3 D-Ala(4)-D-Asn-L-Lys(3) bridges.

146 at nuclear NAC1 binds to histone deacetylase type 4 (HDAC4), hindering phosphorylation of HDAC4 at Se

147 sherbst (weh(Tp85c-/-)) and in patients with type 4 hemochromatosis.

148 encodes 17beta-hydroxysteroid dehydrogenase type 4 (HSD17B4), also known as D-bifunctional protein (

149 lent, followed by type 3, type 2, type 5 and type 4 in that order.

150 shunts (type 3) in one, portovenous shunts (type 4) in three, and both arteriovenous and portovenous

151 4A mutation is also associated with dystonia type 4, in which magnetic resonance images of the brain

152 We administered a phosphodiesterase type 4 inhibitor and dibutyryl cyclic adenosine monophos

153 III clinical trials of the phosphodiesterase type 4 inhibitor apremilast in psoriasis (PSOR), psoriat

154 active, potent, selective phosphodiesterase type 4 inhibitor, which in vitro can affect cells though

155 ing p16 inhibitor of cyclin-dependent kinase type 4 (INK4a) in individuals with melanoma using a popu

156 Pure hereditary spastic paraplegia (SPG) type 4 is the most common form of autosomal dominant her

157 uman HEK293T cell lines, but zebrafish CRY4 (type 4) is not.

158 The autosomal dominant form of the disease, type 4, is due to mutations in the SLC40A1 gene, which e

159 patterns, 10 of which were found among phage type 4 isolates.

160 rboxy-terminal domain of apo(a) containing 6 type-4 kringles (types 5 to 10), kringle V, and the prot

161 ocity encoding to input from lobula columnar type 4 (LC4) visual projection neurons, but the size-enc

162 and thereby cause Leber congenital amaurosis type 4 (LCA4), a severe form of childhood blindness.

163 etinal dystrophy, Leber congenital amaurosis type 4 (LCA4), that manifests as the loss of vision duri

164 l cardiac arrhythmia initially classified as type 4 long QT syndrome.

165 d cardiac arrhythmia, initially described as type 4 long QT syndrome.

166 mbrane adapters, causes dominantly inherited type 4 long-QT cardiac arrhythmia in humans.

167 Mutations in the ankyrin-B gene (ANK2) cause type 4 long-QT syndrome and have been described in kindr

168 lipid phosphate phosphatase-related protein type 4 (LPPR4) (OR, 2.30; P = 4.82 x 10(-6)) and solute

169 a relatively selective muscarinic type 1 and type 4 (M(1) and M(4)) receptor agonist, to determine if

170 cosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase (MT4-MMP, MMP-17) becaus

171 y]), glycolysis (monocarboxylate transporter type 4 [MCT-4]), and angiogenesis (vascular endothelial

172 nnabarinic acid acts as a partial agonist of type 4 metabotropic glutamate (mGlu4) receptors, with no

173 plus T1r3,as well as a truncated form of the type 4 metabotropic glutamate receptor (taste-mGluR4),as

174 Herein we study the ability of type 4 metabotropic glutamate receptors (mGlu4) to regul

175 e interactions between ADAMTS-4 and membrane type 4 MMP (MT4-MMP), protein lysates purified from stim

176 d increased expression of MMP-9 and membrane type 4-MMP as compared with LNCaP and DU-145.

177 d with maturity onset diabetes of the young, type 4 (MODY4) and type 2 diabetes.

178 ula (34%) while Grade 5 was the least common type (4%).MRI showed a high sensitivity of 93.7% and pos

179 BRAF mutation, positive for KRAS mutation); type 4 (MSS or MSI-low, non-CIMP, negative for mutations

180 The type-4 MTs (MT4a and MT4b) conferred greater Zn toleranc

181 In many tissues, type 4 NADPH oxidase is induced upon ischemia or hypoxia

182 pathogenic mutations in KRAS but not BRAF), type 4 (not MSI-high or CIMP, no pathogenic mutations in

183 eactive oxygen species forming NADPH oxidase type 4 (Nox4) as a primary causal therapeutic target.

184 astin staining, and C-X-C chemokine receptor type 4, nuclear factor kappa beta, and tartrate-resistan

185 ic mutations in SLC45A2, associated with OCA type 4 (OCA-4), and G6PC3, associated with neutropenia.

186 45A2 mutations cause oculocutaneous albinism type 4 (OCA4) and polymorphisms are associated with pigm

187 ovirus, with 90% identity in most adenovirus type 4 open reading frames that have been sequenced.

188 ia inhibition of peptidyl arginine deiminase type 4 or abrogation of reactive oxygen species (ROS) pr

189 ship has been termed as cardiorenal syndrome type 4 or cardio-renal link.

190 ell-derived 1 alpha receptor (C-X-C receptor type 4 or CXCR4) using AMD3100 prevented the polarizatio

191 ensin II on other receptors (eg, angiotensin type 4) or lower degradation of growth-inhibitory kinins

192 We demonstrate that the unfolding of wild-type 4-OT in 50 mM phosphate buffers containing 6 M GuHC

193 ced equilibrium unfolding properties of wild-type 4-OT using catalytic activity measurements and usin

194 erstrand NOEs and one turn NOE found in wild-type 4-OT.

195 Drs2p is a resident type 4 P-type ATPase (P4-ATPase) and potential phospholi

196 PFxD motif, which signals for endocytosis, a Type 4 P-Type ATPase was identified and named DnfA.

197 egated within the Spitzenkorper from another Type 4 P-type ATPase, DnfB.

198 Type 4 P-type ATPases (P(4)-ATPases) catalyze phospholip

199 inating enzymes, peptidyl arginine deiminase type 4 (PAD-4), is genetically associated with developme

200 ated proteins and peptidylarginine deiminase type 4 (PAD-4).

201 failure rates of SBC with Type 3 papilla and Type 4 papilla were 11.11% and 6.25%, respectively.

202 cterium tuberculosis-infected mice receiving type 4 PDE-Is (rolipram and cilomilast) and the impact o

203 Type 4 PDE-Is may increase the severity of tuberculosis

204 The type 4 PDE-Is rolipram and cilomilast accelerated the ti

205 Systemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been effective in the tre

206 Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrat

207 t years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suit

208 show that atropine acts as an allosteric PDE type 4 (PDE4) inhibitor.

209 Phosphodiesterase type 4 (PDE4) is a family of enzymes that selectively de

210 leading to upregulation of phosphodiesterase type 4 (PDE4), which catalyzes the hydrolysis of cAMP.

211 Inhibition of type 4 phosphodiesterase (PDE4) and elevation of cyclic

212 Type 4 phosphodiesterase (PDE4) inhibitors are emerging

213 MP cascade and requires participation of the type 4 phosphodiesterase (PDE4), a new role for phosphod

214 monophosphate (cAMP) signaling by increasing type 4 phosphodiesterase catabolism of cAMP when cAMP co

215 Pretreatment with the type 4 phosphodiesterase inhibitor, rolipram, abolished

216 Infusion of the type 4 phosphodiesterase inhibitor, rolipram, prevented

217 MP, cAMP-dependent protein kinase (PKA), and type 4 phosphodiesterase may be involved in attenuating

218 odulator of inflammatory cell responses, and type 4 phosphodiesterases (PDE4) are important regulator

219 Type 4 phosphodiesterases (PDE4) are key cAMP-hydrolyzin

220 r, pretreatment with selective inhibitors of type 4 phosphodiesterases (PDE4), protein kinase A (PKA)

221 ydroxydopamine (6-OHDA) on the expression of type 4 phosphodiesterases (PDE4).

222 Four genes code for type 4 phosphodiesterases (PDE4s), enzymes critical for

223 Bacterial type 4 pili (T4P) are extracellular polymers that initia

224 EHEC) O157:H7 produces long bundles of polar type 4 pili (T4P) called HCP (for hemorrhagic coli pili)

225 bacteria exhibit surface motility powered by type 4 pili (T4P).

226 exhibited twitching motility, which requires type 4 pili (Tfp), and electron microscopy revealed that

227 saccharide, mannose-sensitive haemagglutinin type 4 pili and polar (but not lateral) flagella.

228 This leads to the conclusion that type 4 pili and the DNA translocator are distinct system

229 in complete contrast to the situation in the type 4 pili system homologs, in the T2SS, the major prot

230 tion of how DifA receives input signals from type 4 pili without a prominent periplasmic domain.

231 Bacterial type 2 secretion systems (T2SS), type 4 pili, and archaeal flagella assemble fibres from

232 long, thin fibers, similar in appearance to type 4 pili.

233 for S motility is generated by retraction of type 4 pili.

234 is 46% identical to a Pseudomonas aeruginosa type 4 pilin over its entire length and has all the cons

235 that of a 3D model elaborated from two other type 4 pilin subunits.

236 pseudopilins that are similar in fold to the type 4 pilins.

237 acid sequence of this protein was typical of type 4 pilins.

238 Biogenesis of this type 4 pilus (Tfp) requires a number of structural compo

239 Due to similarities to the type 4 pilus and the type 2 secretion system pseudopilus

240 rotoxigenic Escherichia coli produces a long type 4 pilus called Longus.

241 Toxin-coregulated pilus (TCP), a type 4 pilus expressed by V. cholerae, is a cholera viru

242 larensis Schu S4 strain was found to contain type 4 pilus genes, and we confirmed that these genes ar

243 ndent on orthologues of Type 2 secretion and Type 4 pilus system proteins.

244 t is cleaved off by a cognate membrane-bound type 4 prepilin peptidase (TFPP) during the process of s

245 For example, type 4 prepilin peptidase may contribute to bacterial pa

246 f the family include preflagellin peptidase, type 4 prepilin peptidase, presenilin and signal peptide

247 ), Type 3 units (unknown function; n = 4) or Type 4 (presumed sympathetics; n = 23) units.

248 Spastic paraplegia types 4 (prevalence, 0.91 per 100,000 population), 3 (pr

249 ven regions of the serovar Enteritidis phage type 4 (PT4) chromosome (sequenced at the Sanger Center)

250 an protein tyrosine phosphatase non-receptor type 4 (PTPN4) prevents cell death induction in neurobla

251 tionship between central 5-HT tonus and 5-HT type 4 receptor (5-HT4R) density, suggesting that 5-HT4R

252 cells were transfected with the melanocortin type 4 receptor (MC4-R), but not the type 3 receptor.

253 Activation of serotonin (5-HT) type 4 receptors (5-HT(4)Rs) has been shown to have anxi

254 Similarly, introduction of wild-type 4-repeat tau (tau-4R) into wild-type animals trigge

255 suppressing regulator of G protein signaling type 4 (RGS4) activity, and blocked D1 dopamine receptor

256 radation of regulator of G protein signaling type 4 (RGS4), thus relieving the repression of the Gbet

257 noted between the two volunteers, while the type 4 RPS-reactive serotype was absent in one volunteer

258 hitherto unknown effects of resistant starch type 4 (RS4) enriched diet on gut microbiota composition

259 One cancer-linked locus is the cag type 4 secretion system (cagT4SS), which translocates an

260 ed gene A (CagA), which is translocated by a type 4 secretion system (T4SS) into gastric epithelial c

261 We also demonstrate that the Coxiella type 4 secretion system (T4SS) is critical for the forma

262 We also found that heat-killed NMII and type 4 secretion system (T4SS) mutant NMII were unable t

263 tituent that augments cancer risk is the cag type 4 secretion system (T4SS), which translocates the o

264 en Legionella pneumophila and identified the type 4 secretion system effector Lpg2603 as a remote mem

265 This transfer is often facilitated via type 4 secretion systems (T4SS), which frequently are en

266 s' disease, encodes two virulence-associated type 4 secretion systems (T4SSs), the Dot/Icm type 4B (T

267 ned as Bleeding Academic Research Consortium type 4 severe bleeding, and therefore most bleeding at t

268 stromal-derived factor-1/chemokine receptor type 4 signaling revealed greater functional dependence

269 Using spastic paraplegia type 4 (SPG4, the most frequent HSP subtype) as an exemp

270 t and highly selective binding to human SRIF type 4 (sst(4)) receptors.

271 C. sakazakii sequence type 4 (ST4) was the predominant sequence type of cerebr

272 expressing a family 1 PspA (WU2), a capsular type 4 strain expressing a family 2 PspA (TIGR4), and ge

273 6A strain able to inhibit the growth of the type 4 strain, TIGR4, in vitro.

274 er difficulty in protecting against capsular type 4 strains resulted from differences in their PspAs

275 is less efficacious against several capsular type 4 strains than against strains of capsular types 3,

276 he difficulty in protecting against capsular type 4 strains was eliminated when mice were immunized w

277 adrenergic receptor-C-X-C chemokine receptor type 4 structure as a template, we created a homology mo

278 the number of dermal C-C chemokine receptor type 4(+) T helper type 2 cells, IL-17(+) cells, basophi

279 2 mediastinal and supraclavicular signal) to type 4 (T2 signal into both the mediastinum and the lung

280 length of stay was longer for patients with type 4 than for those with types 1 or 2 (29 days vs 9 da

281 ontan completion was higher in patients with type 4 than in type 1 or 2 (54% vs 2%, respectively; P =

282 The effect of NanA was shown using both type 4 (TIGR4) and type 6A clinical isolates.

283 ll intestine by Vibrio cholerae requires the type 4 toxin co-regulated pilus (TCP).

284 f the transient receptor potential vanilloid type 4 (TRPV4) channel is associated with edema formatio

285 le of transient receptor potential vanilloid type-4 (TRPV4) in itch is unknown.

286 onary transient receptor potential vanilloid type-4 (TRPV4) mechanoreceptors and vagal afferent purin

287 The transient receptor potential vanilloid type 4, TRPV4, is a polymodal cation channel which can b

288 antly shorter time of DSS than patients with type 4 tumors (HR(DSS) 1.66; 95% CI 1.33-2.07), regardle

289 Compared with participants with type 4 tumors (the most predominant), participants with

290 Among non-nociceptive fibres, all Type 4 units exhibited long-lasting supernormality indep

291 For phosphodiesterase type 4 variant 4 (PDE4D4), an enzyme responsible for cyc

292 l-derived factor-1, C-X-C chemokine receptor type 4, vascular endothelial growth factor, and endothel

293 on the backbone of a nonneuroinvasive dengue type 4 virus (DEN4), has been identified as a promising

294 and all other sequences derived from dengue type 4 virus (DEN4).

295 Fab monoclonal antibodies to dengue type 4 virus (DENV-4) were recovered by repertoire cloni

296 The effects of sulfation type (4- vs. 6-sulfation), sulfation pattern (statistica

297 bitor of the cAMP-specific phosphodiesterase type 4, was administered to activate the cAMP cascade, a

298 ce with congenital generalized lipodystrophy type 4, whereas both rMAT and cMAT are preserved in mice

299 ones: 16S type 5 with MenA subgroup III, 16S type 4 with the MenB electrophoretic type 5 (ET-5) compl

300 Clinical outcomes, stratified by stent type, years after PCI were determined from the Vete